Skip to main content
Clinical Trials/NL-OMON50617
NL-OMON50617RecruitingPhase 4

Seizure Treatment IN Glioma (STING): comparing a treatment strategy with levetiracetam versus treatment with valproic acid in glioma patients with a first seizure - Seizure treatment in glioma

eids Universitair Medisch Centrum0 sites120 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Enrollment
120

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • - Histologically proven or suspected diffuse astrocytoma (Isocytrate
  • Dehydrogenase-1 (IDH-1) wildtype or IDH-1 mutated), diffuse oligodendroglioma
  • (IDH-1 mutated and 1p/19q co-deleted), anaplastic astrocytoma (IDH-1 wildtype
  • or IDH-1 mutated), anaplastic oligodendroglioma (IDH-1 mutated and 1p/19q
  • co-deleted), glioblastoma (IDH-1 wild-type or IDH-1 mutated), or diffuse
  • astrocytoma not otherwise specified (NOS), anaplastic astrocytoma NOS,
  • oligodendroglioma NOS, oligoastrocytoma NOS, anaplastic oligoastrocytoma NOS,
  • anaplastic oligodendroglioma NOS or glioblastoma NOS.
  • - Adult patients: >=18 years of age
  • - First epileptic seizure, no longer than 4 weeks ago. Also patients with a
  • glioma, who have had tumor-related epilepsy in the past, can be included if
  • they have been seizure-free for >=2 years without the use AEDs
  • - Monotherapy with antiepileptic drugs is considered most appropriate at the
  • time of randomization
  • - Willing to provide written informed consent

Exclusion Criteria

  • - Treated with antiepileptic drugs for the past 2 years, except emergency
  • treatment in the past 4 weeks
  • - History of non-brain tumor related epilepsy
  • - Pregnancy
  • - Presence of contra-indications for use of levetiracetam or valproic acid

Investigators

Similar Trials